



April 28, 2021

Press Release

Eiken Chemical Co., Ltd.

Representative: Morifumi Wada, President & CEO

Securities code: 4549 (TSE 1st Section)

Contact: Hajime Watari, Manager, Vice
President & Executive Officer

(TEL. 03-5846-3379)

Notice of Distribution of Surplus (Dividend Increase) and Donations to Support Activities in Fight Against COVID-19 Pandemic

Eiken Chemical Co., Ltd. (the “Company”) hereby announces that its Board of Directors resolved at its meeting held on April 28, 2021 to distribute dividends of surplus (year-end dividends) with a record date set at March 31, 2021 as described below. In addition, the Company has made donations to support activities to fight against the COVID-19 infections.

1. Distribution of surplus

(1) Details of dividends

	Amount determined	Most recent dividend forecast (Announced on January 27, 2021)	Results for the fiscal year ended March 31, 2020
Record date	March 31, 2021	Same as on the left	March 31, 2020
Dividend per share	26.00 yen	21.00 yen	17.00 yen
Total amount of dividends	960 million yen	–	626 million yen
Effective date	June 4, 2021	–	June 1, 2020
Source of dividends	Retained earnings	–	Retained earnings

(2) Reason

The Company positions returning profits to shareholders as one of its most important management issues. Its fundamental principle is to implement a stable dividend policy, taking into account the enhancement of internal reserves that are necessary to increase its financial strength and enable proactive business initiatives.

Regarding the year-end dividend for the fiscal year ended March 31, 2021, given that the business results of the fiscal year significantly exceeded the previously announced forecast, the Company decided to pay 26 yen per share, an increase of 5 yen per share.

(Reference) Breakdown of annual dividends

Record date	Dividend per share		
	End of Q2	Year end	Annual
Results for the fiscal year ended March 31, 2021	15.00 yen	26.00 yen	41.00 yen
Results for the fiscal year ended March 31, 2020	13.00 yen	17.00 yen	30.00 yen

2. Donations to support activities to fight against the COVID-19 pandemic

The Company would like to extend its wishes for a speedy recovery of those suffering COVID-19 and for an early end to the pandemic.

Under its management philosophy of “Protect the health of the public through health care services,” the Company has donated approximately 470 million yen for the purpose of providing support to healthcare professionals and other people in health-related fields who are dedicated to responding to COVID-19, hard-to-reach medical settings, people in need of medical care, families and children falling into poverty and others who have lost their places due to the impact of the spread of COVID-19 in each community.

Beneficiaries of donations:

The Sanaburi Foundation (a local fund, part of the 47 prefectural funds for measures against COVID-19), Peace Winds Japan, Tokyo Nursing Association, Red Feather Welfare Fund, Japanese Red Cross Society, United Nations Children’s Fund, The Nippon Foundation, The Stop TB Partnership, Save the Children, etc.

Acknowledging the threats to the people around the world posed by the COVID-19 pandemic, the Company will contribute to achieving a safe and secure society through the provision of genetic testing reagents for COVID-19, which use its proprietary LAMP method technology, and relevant know-how.